Retrospective Study
Copyright ©The Author(s) 2023.
World J Gastroenterol. Nov 28, 2023; 29(44): 5894-5906
Published online Nov 28, 2023. doi: 10.3748/wjg.v29.i44.5894
Table 1 Demographics, operational parameters and outcomes of recipients and donors

Recipient
Donor
Demographics
    Age (yr)49.4 ± 12.848.1 ± 13.1
    Male102 (76.7)111 (83.5)
    Height (cm)168.1 ± 10.2170.6 ± 11.2
    Weight (kg)67.5 ± 18.073.7 ± 17.5
    sTLV (mL)1299 ± 4821311 ± 267
    eTLV by formula (mL)1213 ± 2121287 ± 207
    eTLV by IQQA-3D (mL)1311 ± 522-
    DRI-2.28 ± 0.42
    Cold ischemia time (h)-5.9 ± 1.8
Liver disease
    HBV/HCV85 (63.9)23 (17.3)
    ALD24 (18.0)0
    DILF12 (9.0)0
    Steatosis8 (6.0)43 (32.3)
    Hepatic carcinoma42 (31.6)0
Signs and symptoms
    Moderate or severe ascites69 (51.9)-
    Gastrointestinal bleeding86 (64.7)-
    Hepatic encephalopathy31 (23.3)-
Operational parameters
    Anhepatic phase time (min)50.7 ± 9.0-
    IBL (mL)3117 ± 1725-
    IBT (mL)1949 ± 1749-
Hospitalization Information
    Tracheal extubation time (d)1 (1-3)-
    ICU stay (d)2 (1-6)-
    Postoperative hospital stay (d)15 (11-23)-
Complications
    Massive intraoperative blood loss95 (71.4)-
    EAD caused by SFSS36 (27.1)-
    EAD caused by LFSS20 (15.0)-
    Infection49 (36.8)-
    Incision nonunion29 (21.8)-
Outcomes and follow-up
    Perioperative mortality29 (21.8)-
    Blood loss-specific mortality7 (5.3)-
    EAD-specific mortality17 (12.8)-
    All-cause mortality46 (34.6)-
    Follow-up time (mo)27 (9-44)-